EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Oncoinvent ASA (ONCIN) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Oncoinvent ASA NOK 28.73, price NOK 83.00, upside -65.4%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · NO · ISIN NO0013251173

OA Thin data Sep 24, 2026

Oncoinvent ASA

ONCIN · OL

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 28.73 · Strongly overvalued (−65%)
!Quality 45/100
!Expensive Growth (revenue 3y +316.3 %/yr)
!Low debt · negative free cash flow
✓Ranks above peers (5/8)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Oncoinvent ASA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 138,541 kr 40.70 Fair Value kr 28.73 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 40.70 – kr 138,541 · fair‑value band kr 18.96 – kr 35.92 · the kr 83.00 price screens above the kr 28.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Oncoinvent in your weekly email

Every Wednesday you see whether Oncoinvent is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

Stock analysis

Oncoinvent ASA (ONCIN) currently trades at kr 83.00, while our model-based Fair Value estimate is kr 28.73, implying the stock looks roughly 188.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 18.96 (bear) to kr 35.92 (bull), the price of kr 83.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Oncoinvent ASA reported revenue of 28.1M NOK in FY2025 versus 774K NOK in FY2021, a compound +145.4%/yr. Reported net income was −155M NOK in FY2025.

Key figures

Market cap 372M NOK (≈ $39.0M) · P/S ratio 13.6 · EPS (TTM) kr −125.00 · Return on equity −122% · Return on assets (EBIT) −106% · Operating margin −660% · Revenue (TTM) 28.1M NOK · Revenue growth (YoY) +101%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 104% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −65%, ONCIN screens richer than that median.

Fair Value models

Bear kr 18.96 Fair Value kr 28.73 Bull kr 35.92
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 16.34 kr 21.89 kr 32.67 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 16.34 kr 21.89 kr 32.67 54

Open the full fair value analysis →

Notify me when ONCIN reaches fair value

Put ONCIN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 45 · Market factors (momentum, volatility) 47

Profitability 0
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 58
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 83
Price trend over the last 3–12 months (market factor)
52W Momentum 40
Distance to the 52-week high (market factor)
Net Issuance 50
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3,210.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+316.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−40,628.2% (2021) → −564.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ONCIN screens 189% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oncoinvent ASA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −65% · Below median
Profitability
Return on assets −53% · Bottom 25%
Growth and dividend
Revenue growth 101% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.27× · Cheapest 25%
P/S (TTM) 1.39× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oncoinvent ASA · Fair Value
kr 28.73 −189%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Oncoinvent ASA Fair Value". https://www.fairvalue-calculator.com/stock/ONCIN

Frequently asked questions

Is Oncoinvent ASA (ONCIN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 28.73 versus a price of kr 83.00, about −65% upside (overvalued).
What is the fair value of ONCIN?
Our model-based fair value for Oncoinvent ASA is kr 28.73 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 83.00.
What is the quality score of ONCIN?
Oncoinvent ASA has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncoinvent ASA (ONCIN)?
Our model-based price target is the fair value of kr 28.73 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 18.96, optimistic scenario kr 35.92. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncoinvent ASA stock forecast for 2026?
Our models put fair value at kr 28.73, about −65% upside versus a price of kr 83.00 (overvalued). Cautious scenario kr 18.96, optimistic scenario kr 35.92. The calculation is refreshed regularly with new filings.
What is the revenue of Oncoinvent ASA (ONCIN)?
Oncoinvent ASA reported trailing-twelve-month revenue of about 28.1M NOK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Oncoinvent ASA (ONCIN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncoinvent ASA it is kr 28.73 per share (as of Sep 24, 2026), against a price of kr 83.00. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Oncoinvent ASA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ONCIN trades above its calculated fair value: price kr 83.00, fair value kr 28.73, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONCIN?
No. The price is what the market pays today (kr 83.00); the fair value is what the company's own numbers justify (kr 28.73). For Oncoinvent ASA the two are kr 54.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncoinvent ASA worth?
The market values Oncoinvent ASA at about 372M NOK (market capitalisation, as of Sep 24, 2026). Per share that is kr 83.00; our models calculate a fair value of kr 28.73 per share.
What do the bullish and bearish scenarios say about ONCIN?
Our models span a range for Oncoinvent ASA: cautious scenario kr 18.96, base kr 28.73, optimistic kr 35.92 per share (as of Sep 24, 2026, price kr 83.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oncoinvent ASA (ONCIN)?
Balance-sheet figures for Oncoinvent ASA (as of Sep 24, 2026): return on equity −121.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is ONCIN from its 52-week high?
Oncoinvent ASA trades at kr 83.00, about 41% below its 52-week high of kr 141.50 and 104% above the low of kr 40.70 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 28.73 is for.
Which stocks are comparable to Oncoinvent ASA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncoinvent ASA stock attractive at the current price?
The data as of Sep 24, 2026: price kr 83.00, calculated fair value kr 28.73 (−65%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONCIN calculated?
We run Oncoinvent ASA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 28.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Oncoinvent ASA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncoinvent ASA (ONCIN)?
The closing price on Sep 24, 2026 was kr 83.00. Our model-based fair value is kr 28.73, about −65% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncoinvent ASA right now?
The price sits above even our optimistic bull case (kr 35.92). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 18.96 to kr 35.92) leaves room in how you read the outcome.

Key figures of Oncoinvent ASA

How large is the market capitalisation of Oncoinvent ASA (ONCIN)?
The market capitalisation of Oncoinvent ASA is 372M NOK (≈ $39.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oncoinvent ASA (ONCIN)?
The price-to-sales ratio of Oncoinvent ASA is 13.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oncoinvent ASA (ONCIN)?
Earnings per share at Oncoinvent ASA are kr −125.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Oncoinvent ASA (ONCIN)?
The return on equity (ROE) of Oncoinvent ASA is −122% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oncoinvent ASA (ONCIN)?
On an EBIT basis the return on assets of Oncoinvent ASA is −106% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncoinvent ASA (ONCIN)?
The operating margin of Oncoinvent ASA is −660% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oncoinvent ASA (ONCIN)?
Revenue at Oncoinvent ASA is growing +101% versus a year earlier (3y avg +316%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Oncoinvent ASA (ONCIN) generate?
The free cash flow of Oncoinvent ASA is −131M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Oncoinvent ASA in the live analysis

One click puts Oncoinvent ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.